RNA Therapeutics market Share, Growth Analysis by 2035

by Leowatkins

Roots Analysis has done a detailed study on RNA Therapeutics and RNA Vaccines Market, covering important aspects of the industry and identifying key future growth opportunities.

Key Market Insights
 More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications
 75% of the next generation therapies are still in discovery and preclinical stages, primarily targeting infectious diseases; industry players are actively engaged in advancing their next generation drug portfolio
 Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel RNA therapies and vaccines
 Around 55% of the technologies are used in the development of circular RNA-based therapeutics and vaccines; majority of such technologies facilitate targeted therapy delivery at a specific site within the cell
 Majority of the trials focused on RNA therapeutics and vaccines were registered in 2022; more than 70% of these studies have either been completed / are currently recruiting patients across different locations
 Close to 1,170 patents have been filed / granted for next generation RNA therapeutics and vaccines, by industry and non-industry players, to protect intellectual property generated within this field
 Around 70% of the deals inked in this market were focused on clinical research of saRNA therapeutics / vaccines; of these, more than 60% partnerships were inked for the treatment of infectious diseases
 Several investors, having realized the opportunity within this domain, have invested close to USD 2.9 Billion across various funding rounds in the past four years
 The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years
 The market opportunity associated with next generation RNA therapeutics and vaccines is expected to witness an annualized growth rate of 50% over the coming 12 years
 The estimated market opportunity is expected to be well distributed across various routes of administration, geographical regions and leading players

Table of Contents

1. PREFACE
1.1. RNA Therapeutics and RNA Vaccines Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1. Chapter Overview
3.2. Market Dynamics

4. EXECUTIVE SUMMARY

5. INTRODUCTION
5.1. An Overview of Next Generation RNA Therapeutics and Vaccines
5.2. Key Contributors in the Evolution of Next Generation RNA Therapeutics and Vaccines
5.3. Types of Next Generation RNA Molecules
5.4. Key Aspects of Next Generation RNA Molecules
5.5. Key Challenges Associated with Traditional RNA Modalities
5.6. Advantages of Using Next Generation RNA Modalities

6. MARKET LANDSCAPE
6.1. RNA Therapeutics and RNA Vaccines: Overall Therapies Landscape
6.1.1. Analysis by Type of Modality
6.1.2. Analysis by Type of Molecule
6.1.3. Analysis by Delivery Vehicle
6.1.4. Analysis by Phase of Development
6.1.5. Analysis by Therapeutic Area
6.1.6. Most Active Players: Analysis by Number of Therapies
6.2 RNA Therapeutics and RNA Vaccines: Clinical Stage Therapies Landscape
6.2.1. Analysis by Phase of Development
6.2.2. Analysis by Route of Administration
6.2.3. Analysis by Therapeutic Area
6.3. RNA Therapeutics and RNA Vaccines: Therapy Developers Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters
6.4. RNA Therapeutics and RNA Vaccines: Circular RNA Therapies Landscape
6.4.1. Analysis by Phase of Development
6.4.2. Analysis by Therapeutic Area
6.4.3. Most Active Players: Analysis by Number of Therapies
6.5. RNA Therapeutics and RNA Vaccines: Self-amplifying RNA Therapies Landscape
6.5.1. Analysis by Phase of Development
6.5.2. Analysis by Therapeutic Area
6.5.3. Most Active Players: Analysis by Number of Therapies

7. TECHNOLOGY LANDSCAPE
7.1. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technologies Landscape
7.1.1. Analysis by Class of Molecule
7.1.2. Analysis by Type of Molecule
7.1.3. Analysis by Capabilities of the Technology
7.1.4. Analysis by Therapeutic Area
7.1.5. Analysis by Highest Phase of Development
7.2. RNA Therapeutics and RNA Vaccines: Next Generation RNA Technology / Platform Developers Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Company Size
7.2.3. Analysis by Location of Headquarters
7.2.4. Analysis by Operational Model

8. DRUG PROFILES
8.1. Gemcovac
8.1.1. Developer Overview
8.1.2. Drug Overview
8.1.3. Clinical Trial Information
8.1.4. Clinical Trial Endpoints
8.1.5. Clinical Trial Results
8.1.6. Estimated Sales
8.2. ATYR1923
8.3. ARCT-154
8.4. GRT-C901
8.5. VLPCOV-01
8.6. AVX901
8.7. MTL-CEBPA + Sorafenib
8.8. SLATE

9. CLINICAL TRIAL ANALYSIS
9.1. Analysis Methodology and Key Parameters
9.2. RNA Therapeutics and RNA Vaccines: Clinical Trial Analysis
9.2.1. Analysis by Trial Registration Year
9.2.2. Analysis by Trial Status
9.2.3. Analysis by Trial Registration Year and Trial Status
9.2.4. Analysis by Trial Phase
9.2.5. Analysis by Patients Enrolled
9.2.6. Analysis by Type of Sponsor
9.2.7. Analysis by Therapeutic Area
9.2.8. Analysis by Study Design
9.2.9. Leading Organizations: Analysis by Number of Trials
9.2.10. Analysis by Focus Area
9.2.11. Analysis by Geography

10. PATENT ANALYSIS
10.1. Analysis Methodology and Key Parameters
10.2. RNA Therapeutics and RNA Vaccines: Patent Analysis
10.2.1. Analysis by Type of Patent
10.2.2. Analysis by Patent Publication Year
10.2.3. Analysis by Patent Jurisdiction
10.2.3.1. Analysis by Patent Jurisdiction: North American Scenario
10.2.3.2. Analysis by Patent Jurisdiction: European Scenario
10.2.3.3. Analysis by Patent Jurisdiction: Asia-Pacific Scenario
10.2.4. Analysis by CPC Symbols
10.2.5. World Cloud Analysis: Emerging Focus Areas
10.2.6. Analysis by Patent Age
10.2.7. Leading Industry Players: Analysis by Number of Patents
10.2.8. Leading Non-Industry Players: Analysis by Number of Patents
10.3. RNA Therapeutics and RNA Vaccines: Patent Benchmarking Analysis
10.4. RNA Therapeutics and RNA Vaccines: Patent Valuation Analysis

11. PARTNERSHIPS AND COLLABORATIONS
11.1. Partnership Models
11.2. RNA Therapeutics and RNA Vaccines: Partnerships and Collaborations
11.2.1. Analysis by Year of Partnership
11.2.2. Analysis by Type of Partnership
11.2.3. Analysis by Year and Type of Partnership
11.2.4. Analysis by Year and Type of Molecule
11.2.5. Analysis by Focus of Partnership
11.2.6. Analysis by Purpose of Partnership
11.2.7. Analysis by Therapeutic Area
11.2.8. Most Active Players: Analysis by Number of Partnerships
11.2.9. Analysis by Geography
11.2.9.1. Local and International Agreements
11.2.9.2. Intracontinental and Intercontinental Agreements

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Types of Funding
12.2. RNA Therapeutics and RNA Vaccines: Funding and Investment Analysis
12.3. Analysis by Year of Funding
12.4. Analysis by Type of Funding
12.5. Analysis by Type of Molecule
12.6. Analysis of Amount Invested by Year of Funding
12.7. Analysis of Amount Invested by Type of Funding
12.8. Analysis by Geography
12.9. Analysis by Year and Type of Funding
12.10. Analysis by Purpose of Funding
12.11. Analysis by Stage of Development
12.12. Analysis by Therapeutic Area
12.13. Most Active Players: Analysis by Number of Funding Instances
12.14. Most Active Players: Analysis by Amount Invested
12.15. Leading Investors: Analysis by Number of Funding Instances

13. BIG PHARMA INITIATIVES
13.1. RNA Therapeutics and RNA Vaccines: Big Pharma Initiatives
13.1.1. Analysis by Number of Initiatives
13.1.2. Analysis by Year of Initiative
13.1.3. Analysis by Type of Initiative
13.1.3.1. Analysis by Type of Partnership
13.1.3.2. Analysis by Type of Funding
13.1.4. Analysis by Purpose of Initiative
13.1.5. Analysis by Year and Number of Initiatives
13.1.6. Analysis by Focus of Initiative
13.1.7. Analysis by Location of Headquarters of Big Pharma Players

14. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035
14.1. Key Assumptions and Methodology
14.2. Overall RNA Therapeutics and RNA Vaccines Market, Forecasted Estimates (2023-2035)
14.2.1. Scenario Analysis
14.3. Key Market Segmentations
14.4. Dynamic Dashboard

15. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY
15.1. Therapeutics: Forecasted Estimates (2023-2035)
15.2. Vaccines: Forecasted Estimates (2023-2035)
15.3. Data Triangulation and Validation

16. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE
16.1. repRNA: Forecasted Estimates (2023-2035)
16.2. saRNA: Forecasted Estimates (2023-2035)
16.3. sacRNA: Forecasted Estimates (2023-2035)
16.4. sa-mRNA: Forecasted Estimates (2023-2035)
16.5. tRNA: Forecasted Estimates (2023-2035)
16.6. Data Triangulation and Validation

17. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA
17.1. Infectious Diseases: Forecasted Estimates (2023-2035)
17.2. Oncological Disorders: Forecasted Estimates (2023-2035)
17.3. Pulmonary Disorders: Forecasted Estimates (2023-2035)
17.4. Data Triangulation and Validation

18. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION
18.1. Intradermal Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.2. Intramuscular Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.3. Intravenous Therapeutics and Vaccines: Forecasted Estimates (2023-2035)
18.4. Data Triangulation and Validation

19. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS
19.1. North America: Forecasted Estimates (2023-2035)
19.1.1. US: Forecasted Estimates (2023-2035)
19.2. Europe: Forecasted Estimates (2023-2035)
19.2.1. France: Forecasted Estimates (2023-2035)
19.2.2. Italy: Forecasted Estimates (2023-2035)
19.2.3. Spain: Forecasted Estimates (2023-2035)
19.2.4. UK: Forecasted Estimates (2023-2035)
19.2.5. The Netherlands: Forecasted Estimates (2023-2035)
19.3. Asia-Pacific: Forecasted Estimates (2023-2035)
19.3.1. India: Forecasted Estimates (2023-2035)
19.3.2. Japan: Forecasted Estimates (2023-2035)
19.3.3. Singapore: Forecasted Estimates (2023-2035)
19.4. Data Triangulation and Validation

20. OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS
20.1. Company A
20.2. Company B
20.3. Company C
20.4. Company D
20.5. Company E

21. CONCLUSION

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/rna-therapeutics-market.html

News article
Buffer Preparation Market

Learn from experts: do you know about these emerging industry trends?
Novel Antibody Therapies: Current Scenario and Future Potential
Transforming Biomanufacturing: Potential of Cell Free Systems

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

Contact:
Ben Johnson
+1 (415) 800 3415
Ben.johnson@rootsanalysis.com

You may also like

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?
-
00:00
00:00
Update Required Flash plugin
-
00:00
00:00